Family history of haematological malignancy and prognosis across non‐Hodgkin lymphoma subtypes

George A. Cholack; Raphael Mwangi; Prokop Vodička; Thomas M. Habermann; Verena Hinder; Dennis P. Robinson; Andrew L. Feldman; Thomas E. Witzig; Jose C. Villasboas; Stephen M. Ansell; Brian K. Link; Yucai Wang; Carrie A. Thompson; Susan L. Slager; Matthew Maurer; Anne J. Novak; James R. Cerhan

doi:10.1111/bjh.70397

Back

Family history of haematological malignancy and prognosis across non‐Hodgkin lymphoma subtypes

Journal article

Open access

Peer reviewed

Family history of haematological malignancy and prognosis across non‐Hodgkin lymphoma subtypes

George A. Cholack, Raphael Mwangi, Prokop Vodička, Thomas M. Habermann, Verena Hinder, Dennis P. Robinson, Andrew L. Feldman, Thomas E. Witzig, Jose C. Villasboas, Stephen M. Ansell, …

British journal of haematology

03/10/2026

DOI: 10.1111/bjh.70397

PMID: 41806244

Files and links (1)

url

https://doi.org/10.1111/bjh.70397View

Published (Version of record) Open Access

Abstract

Family history of haematological malignancy (FHHM) reflects inherited susceptibility to non‐Hodgkin lymphoma (NHL), but its prognostic significance remains poorly understood. We used a cohort study of 1994 NHL patients to evaluate associations between FHHM and clinical outcomes across lymphoma subtypes. We estimated associations, adjusted for sex and lymphoma‐specific prognostic index, of self‐reported FHHM in a first‐degree relative with overall survival (OS), event‐free survival (EFS) and lymphoma‐specific survival (LSS) using multivariable Cox regression models and with failure to achieve EFS at 24 months (EFS24) using logistic regression. FHHM prevalence was 12.8%, and the median follow‐up among survivors was 12.0 years. FHHM was not associated with OS. In subtype‐specific analyses, FHHM was associated with inferior LSS (hazard ratio [HR] = 1.98, 95% confidence interval [CI] 1.11–3.53) in follicular lymphoma (FL); this association and the association with EFS24 failure strengthened among those treated with front‐line immunochemotherapy (EFS24 failure odds ratio = 2.57, 95% CI 1.08–5.99; LSS HR = 2.68, 95% CI 1.09–6.58). In mantle cell lymphoma, FHHM was associated with inferior EFS (HR = 1.70, 95% CI 1.02–2.85). Interaction testing did not demonstrate significant heterogeneity of FHHM effects by lymphoma subtype. FHHM may be associated with adverse outcomes in select NHL groups, particularly FL. These findings warrant further investigation of germline and environmental factors potentially contributing to more aggressive FLs.

Details

Title: Subtitle: Family history of haematological malignancy and prognosis across non‐Hodgkin lymphoma subtypes
Creators: George A. Cholack - Mayo Clinic
Raphael Mwangi - Mayo Clinic in Florida
Prokop Vodička - Charles University
Thomas M. Habermann - Mayo Clinic
Verena Hinder - Mayo Clinic in Florida
Dennis P. Robinson - Mayo Clinic in Florida
Andrew L. Feldman - Mayo Clinic
Thomas E. Witzig - Mayo Clinic
Jose C. Villasboas - Mayo Clinic
Stephen M. Ansell - Mayo Clinic
Brian K. Link - University of Iowa
Yucai Wang - Mayo Clinic
Carrie A. Thompson - Mayo Clinic
Susan L. Slager - Mayo Clinic
Matthew Maurer - Mayo Clinic
Anne J. Novak - Mayo Clinic
James R. Cerhan - Mayo Clinic in Florida
Resource Type: Journal article
Publication Details: British journal of haematology
DOI: 10.1111/bjh.70397
PMID: 41806244
NLM abbreviation: Br J Haematol
ISSN: 0007-1048
eISSN: 1365-2141
Publisher: Wiley
Language: English
Electronic publication date: 03/10/2026
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Epidemiology; Internal Medicine
Record Identifier: 9985147185602771

Metrics

1 Record Views